In the phase III GO-RAISE trial , 356 patients were randomized to placebo with crossover to golimumab 50 mg at Week 24 ( n = 78 ) , golimumab 50 mg ( n = 138 ) , or golimumab 100 mg ( n = 140 ) at baseline and every 4 weeks .